Korean J Urol.  2007 Aug;48(8):765-770. 10.4111/kju.2007.48.8.765.

Clinical Role of F-18 Fluorodeoxyglucose Positron Emission Tomography for Follow-up of Patients with Renal Cell Carcinoma

• Kim GH
• Jo MK
• Cheon GJ
• Lee HM

• KMID: 2061267
• DOI: http://doi.org/10.4111/kju.2007.48.8.765

Abstract

PURPOSE: To evaluate the role of [(18)F]fluorodeoxyglucose-positron emission tomography(FDG-PET) for the follow-up of patients with a renal cell carcinoma(RCC), and compare FDG-PET with conventional imaging modalities, including computerized tomography(CT), chest PA, bone scan and brain magnetic resonance imaging(MRI).
MATERIALS AND METHODS
FDG-PET and conventional imaging techniques, includingCT, chest PA, bone scan and brain MRI, were performed on 69 patients who had undergone a radical nephrectomy and/or metastatectomy, with a final pathological diagnosis of a RCC. The final diagnoses of recurrences/metastases were established from the histopathological or clinical findings.
RESULTS
Recurrences and metastases were present at 47 sites(34 patients). The results of FDG-PET were true positive and false negative in 44 and 3 of the 47 sites, respectively. The results of conventional imaging techniques were true positive and false negative in 40 and 7 of the 47 sites, respectively. The results of FDG-PET were true negative and false positive in 34 and 1 of the 35 patients, respectively. The results of conventional imaging techniques were true negative and false positive in 30 and 5 of the 35 patients, respectively. Therefore, FDG-PET was more sensitive, specific and accurate than conventional imaging techniques for the follow-up of patients with a RCC.
CONCLUSIONS
FDG-PET accurately detected the postoperative recurrences and metastases in patients with a RCC. FDG-PET may have a role in the follow-up of patients with a RCC.

Keyword

18F fluorodeoxyglucose; Positron emission tomography; Renal cell carcinoma

MeSH Terms

Brain
Carcinoma, Renal Cell*
Diagnosis
Electrons*
Fluorodeoxyglucose F18
Follow-Up Studies*
Humans
Magnetic Resonance Imaging
Neoplasm Metastasis
Nephrectomy
Positron-Emission Tomography*
Recurrence
Thorax
Fluorodeoxyglucose F18

Reference

References

1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996; 335:865–75.

2. Delbeke D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med. 1999; 40:591–603.

3. Scott AM, Larson SM. Tumor imaging and therapy. Radiol Clin North Am. 1993; 31:859–79.

4. Rigo P, Paulus P, Kaschten BJ, Hustinx P, Bury T, Jerusalem G, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med. 1996; 23:1641–74.

5. Lee SW, Jo MK, Lee HM. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for diagnosis and staging of renal tumors. Korean J Urol. 2004; 45:299–302.

6. Flanigan RC, Yonover PM, Campbell SC. Role of nephrectomy in metastatic renal cell carcinoma. AUA Update Series. 2002; 21:242–7.

7. Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol. 1996; 14:700–8.

8. McGuirt WF, Greven K, Williams D 3rd, Keves JW Jr, Watson N, Cappellari JO, et al. PET scanning in head and neck oncology: a review. Head Neck. 1998; 20:208–15.

9. Safaei A, Figlin R, Hoh CK, Silverman DH, Seltzer M, Phelps ME, et al. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol. 2002; 57:56–62.

10. Ramdave S, Thomas GW, Berlangieri SU, Bolton DM, Davis I, Danguy HT, et al. Clinical role of F-18 fluorodeoxyglucose positron-emission tomography for detection and management of renal cell carcinoma. J Urol. 2001; 166:825–30.

11. Thrasher JB, Paulson DF. Prognostic factors in renal cancer. Urol Clin North Am. 1993; 20:247–62.

12. Thrasher JB, Clark JR, Cleland BP. Surgery for pulmonary metastases from renal cell carcinoma. Army experience from 1977–1987. Urology. 1990; 35:487–91.

13. Janzen NK, Laifer-Narin S, Han KR, Seltzer M, Thomas MA, Pantuck AJ, et al. Emerging technologies in uroradiologic imaging. Urol Oncol. 2003; 21:317–26.

14. Wu HC, Yen RF, Shen YY, Kao CH, Lin CC, Lee CC. Comparing whole body 18F–2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas – a preliminary report. J Cancer Res Clin Oncol. 2002; 128:503–6.

15. Harrison J, Ali A, Bonomi P, Prinz R. The role of positron emission tomography in selecting patients with metastatic cancer for adrenalectomy. Am Surg. 2000; 66:432–6.